HOW CAR-T
THERAPY WORKS
The full sequence from cell collection to infusion โ what happens at each step, how long it takes, and what patients need to know before starting.
Not Like Starting a Drug
CAR-T therapy is closer to a manufacturing process than a prescription. The patient's own biology is the raw material. From decision to infusion takes 3-5 weeks, with each step serving a specific purpose. Understanding the full sequence helps patients prepare for what is a significant but structured commitment.
โThe manufacturing isn't a logistical inconvenience โ it's the mechanism. The personalisation is the treatment.โ
The CAR-T Treatment Process
Seven distinct phases from cell collection to recovery.
- 1
Leukapheresis (Cell Collection)
Blood drawn through a catheter; a machine separates T-cells and returns everything else. Takes 3-6 hours. Fatigue and mild calcium dip are common.
- 2
Genetic Engineering
T-cells sent to a specialist lab. A lentiviral vector delivers the CAR gene โ the receptor that will lock onto cancer cells.
- 3
Cell Expansion
Modified cells multiply from millions into hundreds of millions or more. This is the step that takes the most time.
- 4
Quality Control
Product tested for potency, identity, and safety. Must pass all checks before release. Occasionally a batch doesn't pass.
- 5
Lymphodepletion Chemotherapy
Fludarabine and cyclophosphamide for 3 days. Clears immune space for CAR-T cells to expand and persist.
- 6
CAR-T Infusion
IV administration taking less than an hour. The complexity is not the infusion โ it's the days that follow.
- 7
Post-Infusion Monitoring
Inpatient for 7-14 days. CRS and ICANS monitoring with vital signs, neuro checks, and cytokine levels tracked continuously.
What Happens During Manufacturing?
Most patients receive bridging therapy to keep disease stable while waiting for the product. The type depends on cancer type, progression speed, and prior treatments.
The Waiting Window
3-5 weeks where the patient's disease needs to remain manageable. If deterioration is significant, the window can close.
Bridging Treatment
Hold-the-line therapy โ not curative, but stabilising. Specific regimen chosen based on cancer type and urgency.
Frequently Asked Questions
About the CAR-T Process
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Understand What the Process Involves for Your Case?
A specialist consultation walks through the specific timeline and logistics for your situation. Upload your reports to start.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.